S&P 5007,580.07▼1.8% Nasdaq25,437.00▼2.9% Dow51,770.31▼1.1% Russell 2K2,811.84▼1.7% 10-Yr4.93%−6bp VIX19.42+2.22 WTI$102.95▲0.9% Gold$3,884.90▼3.6% EUR/USD1.118▲0.2% BTC$77,597▲0.2% Nikkei64,659▲1.1%
At close · Sat, Oct 31, 2026
Daily Market Updates.

Earnings

Home›Earnings›Results›Eli Lilly’s First Full Medicare Quarter: Is Volume Sti…

Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?

Reported · Written up by our desk · Results

Eli Lilly posted 39% YOY revenue growth in Q3 2026 on strong Mounjaro and Zepbound sales, raising full-year guidance even as Medicare's GLP-1 Bridge program pressures drug pricing.

← Newer storyCrash! Gold price suffers worst October in years: Did silver and plat…

More like this

EarningsMarvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
EarningsExxon's Refining Profits Soared,Did Chevron Get the Same Windfall?
EarningsOracle's AI Spending Peak Is in Sight,Can the Stock Recover?
EarningsLyondellBasell's Dividend Looks Safer, But a New Risk Could Change That
EarningsL3Harris Stock Took a Beating,Is a 20% Rebound Next?

Sources

MarketBeat RatingsEli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.